David P. Ryan appointed to board; Ansbert Gadicke resigns as director at Cullinan Oncology

Cullinan Therapeutics, Inc.

David P. Ryan, M.D. appointed as Class II director effective Nov 1, 2022.
Dr. Ryan brings over 20 years of oncology experience; Clinical Director at MGH Cancer Center since 2012.
Received option grant with $250,000 fair value, vesting one-third annually over three years.
Ansbert Gadicke, M.D. resigned as director effective Nov 1, 2022; no disagreement with Company.
Dr. Ryan appointed to Compensation Committee.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Ansbert Gadicke

director

CGEM · Cullinan Therapeutics, Inc.

Effective: 2022-11-01
Filed: November 2, 2022, 7:59 PM ET

Ansbert Gadicke, M.D. notified the Board of his intention to resign as a director effective as of November 1, 2022.

Appointed

David P. Ryan

Class II director

CGEM · Cullinan Therapeutics, Inc.

Effective: 2022-11-01
Filed: November 2, 2022, 7:59 PM ET

appointed David P. Ryan, M.D. as a Class II director, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Ansbert Gadicke resigned as director at Cullinan Therapeutics, Inc..

Action: resigned
Role: director

Exact text from the filing

Ansbert Gadicke, M.D. notified the Board of his intention to resign as a director effective as of November 1, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

David P. Ryan was appointed as Class II director at Cullinan Therapeutics, Inc..

Action: appointed
Role: Class II director

Exact text from the filing

appointed David P. Ryan, M.D. as a Class II director, effective immediately.

View on SEC.gov

Cullinan Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-275466

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.